Dr. Dilsher Singh Dhoot, MD

Dr. Dhoot practices at California Retina Consultants in Bakersfield, California.

Dr. Dhoot's NPI, 1508070566, was assigned on May 9, 2007. Dr. Dhoot graduated from OHSU School of Medicine in 2006. Dr. Dhoot's California license number on file is A119711.

Dr. Dhoot's primary practice is California Retina Consultants, at 5555 Business S Park, Bakersfield, CA 93309 in Kern County. The practice phone is (661) 325-4393.

Dr. Dhoot's primary practice is California Retina Consultants in Bakersfield, California. Dr. Dhoot is also affiliated with Henry Mayo Newhall Hospital. Dmand AI also links Dr. Dhoot to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dhoot practices, 2 sites in all. Vendor and product names are available with a free account.

Retina specialist is Dr. Dhoot's primary specialty in the NPI Registry, under taxonomy code 207WX0107X. Dr. Dhoot is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Dhoot's licenses on file in 3 states: California, Oregon and Ohio.

Dmand AI lists age-related macular degeneration, cataract, conjunctivitis, dry eye, eyelid inflammation, glaucoma, hypertensive retinopathy and inflammation of iris among the conditions Dr. Dhoot treats.

CMS data shows 62,334 Medicare services from Dr. Dhoot across 28 procedure codes in 2024, for 1,922 Medicare patients. Medicare paid $5,826,161 for them.

CMS counts 1,922 Medicare patients who saw Dr. Dhoot in 2024. The largest group is 65 to 74, with 787 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 27% are also on Medicaid. Their average risk score is 1.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dhoot's median patient age at 68, with 56% women.

In 2024, Dr. Dhoot wrote 1,727 Medicare Part D claims for 403 patients. 65% of them were for generic drugs. CMS names the drug for 1,628 of them, across 19 drugs with 11 or more claims each, at $57,796 in total drug cost. In 2023, CMS named 1,304 claims across 15 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Dhoot for performance year 2024, reported as part of a group. Dr. Dhoot accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 43 papers to Dr. Dhoot, published from 2010 to 2025. 2017 was the busiest year, with 3. The most frequent topics are Intravitreal Injections, Angiogenesis Inhibitors and Diabetic Retinopathy. Dr. Dhoot has published most often in Ophthalmol Retina. Dr. Dhoot's most frequent co-authors are Robert Logan Avery, MD, Nathan Christopher Steinle, MD and Alessandro Attilio Castellarin, MD.

Dmand AI links Dr. Dhoot to 3 clinical trials. Conditions studied include Diabetic Retinopathy, Glaucoma, Neovascular and Diabetic Angiopathies. Regeneron Pharmaceuticals sponsors the most, 2. Open Payments lists research payments to Dr. Dhoot that name 3 trials.

CMS Open Payments shows 2,145 general payments to Dr. Dhoot from 36 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 60% of the total. Regeneron Pharmaceuticals, Inc. paid the most, $900,469. It also lists 72 research payments totaling $160,986 from 2016 to 2025, naming 3 clinical trials.

Dr. Dhoot graduated from OHSU School of Medicine in 2006.

Dr. Dhoot is in network with 18 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.